The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Related Articles
ESH-iCMLf 27th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy | ESH – European School of Haematology
Chairs : Jorge Cortes, Tim P. Hughes, Daniela S. Krause October 10-12, 2025 – Estoril, Portugal Chairs: Jorge Cortes, Tim P. Hughes, Daniela S. Krause…
Don’t over-do MRIs for headache – Medical Republic
Trying to reassure headache patients by ordering brain scans can have the opposite effect, a leading expert says.
DCIS: should we stop calling it “breast cancer”?
Renewed calls to minimise the overdiagnosis and unnecessary treatment of breast abnormalities
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer | NEJM
In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against…
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…
Study Highlights Global Trends in Risk Factors Linked to Lung Cancer Deaths – InventUM
A new study by Sylvester researchers used trends in tracheal, bronchial and lung cancer deaths to emphasize the need for policy vigilance.
Study by Sylvester, Collaborators Highlights Global Trends in Risk Factors Linked to Lung Cancer Deaths | Newswise
Lung and related cancer deaths decreased in the world’s 10 most populous countries over the past 40 years, but there is still a pressing need…
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
Key PointsAdding navitoclax to ongoing ruxolitinib demonstrates durable responses and potential disease modification in relapsed/refractory MF.Thrombocytop
